This article is more than 5 years old. Information may no longer be current.
Tissue of origin test now covered by Medicare
The Pathwork Tissue of Origin Test — the only FDA-cleared molecular diagnostic test for tissue of origin — will now be covered for all Medicare patients across the nation, according to a company press release. A positive coverage policy for the test has been issued by Palmetto GBA, the contractor that administers Medicare in the state of California. The test helps identify the primary tumor in metastatic disease or those with a complex clinical history.
“Cancers are best treated according to their respective sites of origin and tissue type,” Karo K. Arzoo, MD, oncologist at the Roy and Patricia Disney Family Cancer Center; chair of hematology and oncology at Providence Saint Joseph Medical Center in Burbank, Calif. and clinical instructor at University of Southern California Norris Comprehensive Cancer Center in Los Angeles, Calif., said in a press release. “This is true even when the disease is metastatic at the time of diagnosis.”
The test (Pathwork Tissue of Origin Test, Pathwork Diagnostics, Inc.) has been evaluated in multiple independent studies published in both the Journal of Clinical Oncology and the Journal of Molecular Diagnostics.
 |
Follow HemOncToday.com on Twitter. |